Pharmacological interventions in acute respiratory distress syndrome by Antoine Roch et al.
Roch et al. Annals of Intensive Care 2013, 3:20
http://www.annalsofintensivecare.com/content/3/1/20REVIEW Open AccessPharmacological interventions in acute respiratory
distress syndrome
Antoine Roch1,2,3*, Sami Hraiech1,2, Stéphanie Dizier2 and Laurent Papazian1,2Abstract
Pharmacological interventions are commonly considered in acute respiratory distress syndrome (ARDS) patients.
Inhaled nitric oxide (iNO) and neuromuscular blockers (NMBs) are used in patients with severe hypoxemia. No
outcome benefit has been observed with the systematic use of iNO. However, a sometimes important
improvement in oxygenation can occur shortly after starting administration. Therefore, its ease of use and its good
tolerance justify iNO optionally combined with almitirne as a rescue therapy on a trial basis. Recent data from the
literature support the use of a 48-h infusion of NMBs in patients with a PaO2 to FiO2 ratio <120 mmHg. No strong
evidence exists on the increase of ICU-acquired paresis after a short course of NMBs. Fluid management with the
goal to obtain zero fluid balance in ARDS patients without shock or renal failure significantly increases the number
of days without mechanical ventilation. On the other hand, patients with hemodynamic failure must receive early
and adapted fluid resuscitation. Liberal and conservative fluid strategies therefore are complementary and should
ideally follow each other in time in the same patient whose hemodynamic state progressively stabilizes. At present,
albumin treatment does not appear to be justified for limitation of pulmonary edema and respiratory morbidity.
Aerosolized β2-agonists do not improve outcome in patients with ARDS and one study strongly suggests that
intravenous salbutamol may worsen outcome in those patients. The early use of high doses of corticosteroids for
the prevention of ARDS in septic shock patients or in patients with confirmed ARDS significantly reduced the
duration of mechanical ventilation but had no effect or even increased mortality. In patients with persistent ARDS
after 7 to 28 days, a randomized trial showed no reduction in mortality with moderate doses of corticosteroids but
an increased PaO2 to FiO2 ratio and thoracopulmonary compliance were found, as well as shorter durations of
mechanical ventilation and of ICU stay. Conflicting data exist on the interest of low doses of corticosteroids
(200 mg/day of hydrocortisone) in ARDS patients. In the context of a persistent ARDS with histological proof of
fibroproliferation, a corticosteroid treatment with a progressive decrease of doses can be proposed.
Keywords: Acute respiratory distress syndrome; Nitric oxide; Neuromuscular blockers; Fluids; Albumin;
Corticosteroids; Hypoxemia; Fibrosis; Rescue therapy; OutcomeReview
Introduction
Dysregulated inflammation, accumulation and activity of
leukocytes and platelets, uncontrolled activation of co-
agulation and altered permeability of alveolar endothelial
and epithelial barriers leading to pulmonary edema are
key points in the pathophysiology of acute lung injury
and acute respiratory distress syndrome (ARDS) [1]. ARDS
results in impaired gas exchange and hypoxemic respiratory* Correspondence: antoine.roch@ap-hm.fr
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in any medium, provided the original work is pfailure, which can be refractory and life-threatening [2].
Besides ventilatory support, pharmacological interventions
are commonly considered throughout the course of ARDS.
Some of these interventions affect supportive care, such as
fluid management or neuromuscular blockers (NMBs),
whereas others are focused on recovery from hypoxemia or
have been studied in patients with persistent ARDS. The
present review will summarize clinical results and practical
aspects of pharmacological interventions, which are more
largely used by clinicians. The current evidence about
inhaled nitric oxide, almitrine, NMBs, fluid manage-
ment, β2-agonists, and corticosteroids will be addressed
successively.Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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Inhaled nitric oxide (iNO) selectively vasodilates the pul-
monary vasculature in ventilated alveoli, which improves
ventilation-perfusion matching and hypoxemia and lowers
pulmonary arterial pressure. Its administration via the in-
haled route and its very short half-life minimize systemic
effects (i.e., hypotension) [3]. In randomized, clinical trials
(RCTs) [4-8], iNO was associated with a transient im-
provement in oxygenation in adults with ARDS. However,
no survival benefit or reduction in ventilator-free days has
been observed. In a systematic review and meta-analysis
of patients with acute lung injury (ALI) or ARDS from 12
trials, iNO was associated with modest improvements in
oxygenation (13% of increase in PaO2 to FiO2 ratio until
day 3-4 of administration), no effect on mean pulmonary
artery pressure, and no effect on survival or duration of
mechanical ventilation [9]. However, available RCTs do
not resolve the question of whether iNO leads to any
clinically significant benefits in certain subgroups of
patients, such as those with severe hypoxemia not
responding to conventional treatment [10]. In this sense,
iNO is frequently used as a rescue therapy. For example,
iNO was used during ICU stay in respectively 30% and
20% of ARDS patients included in two large RCTs [11,12].
Moreover, iNO was used for refractory hypoxemia in 32%
of the patients subsequently treated with ECMO during
the 2009 H1N1 pandemic in Australia/New Zealand [13].
When defining a positive response as an increase of at
least 20% of PaO2 to FiO2 ratio, about half of patients are
responders to iNO [6,14]. However, because improve-
ment in oxygenation can be dramatic in the setting of
life-threatening hypoxemia and because no radiological
or physiological predictive factor of response has been
identified [15,16], its use can be supported in this setting on
a trial basis, what may buy time for the institution of other
means of support. Clinically significant improvement in
oxygenation following initiation of iNO should be demon-
strated within the first hour of therapy to justify continued
use. A maximal oxygenation benefit typically occurs with
doses as low as 0.1 to 2 ppm [17] and always with doses of
less than 20 ppm [18]. Worsening of oxygenation has been
frequently documented with doses above 20 ppm [19]
or even above 10 ppm [18]. Moreover, the dose-response
curve has been shown to shift progressively to the left in
patients receiving iNO continuously for several days [20],
implying that the optimal dose of iNO must be determined
by titration against the therapeutic target in each patient at
least each day. INO has additive effects on oxygenation
with prone positioning [21] and with high frequency oscilla-
tory ventilation [22]. The effect of iNO is not influenced by
the administration of vasopressive agents, such as norepin-
ephrine [23,24], but iNO has additive effects on oxygen-
ation with almitrine, a selective pulmonary vasoconstrictor
[25,26]. A progressive iNO weaning on several hours issuggested due to the risk of oxygenation worsening,
pulmonary artery pressure increase, and hemodynamic
collapse in case of sudden discontinuation [14]. INO
may contribute to the formation of cytotoxic reactive
nitrogen species and reactive oxygen species, especially
when administered with high concentrations of oxygen
[27]. This is minimized by limiting FiO2, by introducing
iNO into the inspiratory limb of the ventilator tubing as
near to the patient as possible [28] and by synchronizing
injection of iNO with inspiration [29]. Up to 40 ppm of
iNO should not cause methemoglobinemia in adults in
the absence of methemoglobin reductase deficiency [30].
Experimentally, almitrine increases hypoxic pulmonary
vasoconstriction, except where strong vasoconstriction is
already present [31]. In patients with ARDS, almitrine
causes a redistribution of blood flow to well-ventilated
areas and improves oxygenation [32] while increasing
pulmonary artery pressure [33-35]. It is suggested that
low-dose almitrine enhances hypoxic pulmonary vasocon-
striction, whereas at high doses (>20 μg/kg/min), it would
induce diffuse and inefficient vasoconstriction [36,37]. In
this sense, dosages of 2 to 4 μg/kg/min have been shown
to be optimal in most patients [34,38,39]. Almitrine has
additive effects on oxygenation with iNO in approximately
two thirds of iNO responders [25,38]. However, some
patients may be responders to almitrine while they did not
respond to iNO [25,38]. The effectiveness of almitrine on
oxygenation often is reduced in septic patients receiving
norepinephrine [23,24]. Therefore, the use of higher doses
of almitrine (16 μg/kg/min) may produce further improve-
ment in oxygenation in patients receiving norepinephrine if
they are responders to iNO [26]. The efficiency of prolonged
administration of almitrine has not been evaluated. Because
of an increased pulmonary artery pressure, high doses of
almitrine (16 μg/kg/min) may result in reduced right ven-
tricular ejection fraction [40]. Therefore, almitrine is not
recommended in patients with severe pulmonary hyperten-
sion or acute cor pulmonale. The prolonged administration
of almitrine has been involved in peripheral neuropathies in
COPD patients [41,42]. This complication was usually
associated with circulating levels >400 ng/ml. While
intravenous administration of 16 μg/kg/min of almitrine in
patients with ARDS was associated with levels >400 ng/ml
in 16 of 17 patients, a dosage of 4 μg/kg/min resulted in
high levels in only one patient [32], suggesting that this
dosage would be safe on the neurological function. The
almitrine also may have liver toxicity [43]. A reversible and
dose-dependent increase in lactate level associated with
impaired liver function was observed in 8 of 25 patients in
the first 24 hours of administration of 2 of 8 μg/kg/min of
almitrine [43]. As for iNO, a frequent and quick effect
on oxygenation supports the optional use of almitrine
in patients with very severe hypoxemia on a trial basis,
until the institution of other means of support. The absence
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minutes does not justify any continued administration.
Neuromuscular blockers
Several studies have reported the frequent use of neuro-
muscular blockers (NMBs) in severe ARDS patients,
reaching 40-50% in several recent RCTs [12,44,45]. One
of the main reasons to justify the use of NMBs in ARDS
is facilitation of mechanical ventilation and control of
patient/ventilator asynchrony. Arroliga et al. [46] found
that the factors associated with a more frequent NMB
use were mainly related to the severity of the lung dis-
ease, such as the presence of ARDS criteria, high plateau
pressures, and also by the use of prone positioning, high
PEEP levels, or nonconventional modes of ventilation,
such as high-frequency oscillatory ventilation [47]. Several
recent studies have shown an improvement in oxygenation
with the use of NMBs in ARDS patients [11,48-50]. In the
studies by Gainner et al. [49] and Forel et al. [50], patients
randomized to the NMB group had a higher PaO2 to FiO2
ratio at 48, 96, and 120 h after randomization. In contrast,
there was no change in the PaO2 to FiO2 ratio 1 h after
randomization in the NMB group. The decrease in plateau
pressure and PEEP requirements during the 120-h study
period were more marked in the NMB group. Recently, a
larger RCT confirmed these results [11], showing a PaO2 to
FiO2 ratio on day 7 higher in patients receiving a 48-h
continuous cisatracurium infusion than in the control
group. In this multicenter, double-blind trial [11], 339
patients presenting with severe ARDS within the previous
48 h (i.e., PaO2 to FiO2 ratio <150 mmHg with PEEP of at
least 5 cm H2O) were randomly assigned to receive either
cisatracurium besylate (bolus of 15 mg i.v., then 37.5 mg/h
infusion for 48 h) or placebo for 48 h. The group of
patients treated with cisatracurium had a higher adjusted
90-day survival rate compared with those who received
placebo (hazards ratio (HR) 0.68; 95% confidence interval
(CI) 0.48–0.98; p = 0.04). It is noteworthy that the benefi-
cial effect of cisatracurium on mortality was limited to the
patients presenting a PaO2 to FiO2 ratio of less than
120 mmHg. These results were recently confirmed in a
meta-analysis [51]. The observed improvements in
mortality and gas exchange raise the question of the
mechanisms involved. The positive effects of NMBs
could be related to a decrease in ventilator induced
lung injury, as suggested by the decreased incidence of
barotrauma and pneumothoraces in the cisatracurium
group [11]. NMBs also could reinforce the beneficial
effect of lung-protective mechanical ventilation in patients
with ARDS through a reduction in biotrauma. Forel et al.
[50] showed that after 48 h of NMB infusion in ARDS
patients, pulmonary concentrations of IL-1b, IL-6, and
IL-8, as well as serum concentrations of IL-1b and IL-6
were lower than in the control group. This hypothesis isreinforced by the observed decrease in the number of organ
failures in the cisatracurium group of the ACURASYS
study [11], possibly as a result of less biotrauma. NMBs also
could help to avoid patient–ventilator dyssynchrony and
limit end-expiratory collapse by inhibiting active expiration,
limiting derecruitment, and maintaining PEEP [52]. More-
over, in some patients, inspiratory efforts could lead to
global or regional increases in transpulmonary pressure that
can be deleterious [53]. These recent data from the litera-
ture provide a strong argument for beneficial effects of
NMBs during the early phase of severe ARDS and support
the use of a 48-h infusion of cisatracurium in patients with
more hypoxemic ARDS (particularly with a PaO2 to FiO2
ratio <120 mmHg). However, risks of using NMBs have
been reported and have resulted in controversy regarding
the use of these agents in ARDS patients. The incidence of
ICU-acquired weakness is 34–60% in patients with ARDS
[54]. Administration of NMBs does not appear to be an
independent risk factor for ICU-acquired weakness [55] if
they are not given with corticosteroids or in patients with
hyperglycemia [56]. In the ACURASYS study [11], the inci-
dence of ICU-acquired paresis was not higher in patients
receiving NMBs than in the control group. Hypersensitivity
reactions occurring after administration of NMBs are a
major cause for concern. A recent survey [57] of hypersen-
sitivity reactions observed during anesthesia showed that
cisatracurium was involved in 5.9% of anaphylaxis episodes.
Finally, paralyzing patients highlights the problem of
inadequate sedation [58].
Fluid management
In the early phase of ARDS, an associated septic state
is usually responsible for hypovolemia. At this stage,
hemodynamic optimization by early and adapted fluid
loading has proven its prognostic value [59] and a fluid
restriction strategy can result in hemodynamic aggravation
and dysfunctions of associated organs, determining the
mortality of patients presenting ARDS [60]. Nevertheless,
ARDS is particularly characterized by pulmonary edema
due to an increase in pulmonary capillary permeability.
Edema has an impact on respiratory function at several
levels: decrease in compliance, hypoxemia, alteration of
surfactant, pulmonary hypertension [61]. Thus, any attempt
to reduce edema potentially can have beneficial effects on
respiratory function and eventually outcome. Several stud-
ies have suggested a prognostic role of the quantity of lung
water in ARDS patients [62-64]. Moreover, large cohort
studies have shown that positive fluid balance was associ-
ated with higher mortality in patients with acute lung
injury or ARDS [65] or in patients with septic shock [66].
However, to date, no study evaluated strategies specifically
designed to reduce lung water content and to evaluate
their prognostic impact. Fluid restriction that is more or
less associated with a diuretic treatment makes possible to
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ous pressure (CVP) due to lung edema resorption through
an improvement in venous return. A randomized, multi-
center study evaluated a strategy of fluid restriction that
was more or less associated with diuretic treatment pre-
scribed in the absence of hypotension and renal failure in
patients with acute lung injury or ARDS [67]. Patients
were included in the study approximately 48 hours after
admission to the ICU. The decision to submit patients to
fluid loading or diuretic treatment depended on the pres-
ence of oliguria and the level of CVP. Schematically, the
purpose was to obtain a CVP of 8 mmHg or less in the
“conservative-strategy” group or 14 mmHg in the “liberal-
strategy” group. The protocol was applied for 7 days after
inclusion of the patient but was not applied in cases of
hypotension. The conservative strategy resulted in zero
fluid in 7 days, whereas the fluid results in the liberal-
strategy were +6 liters over 7 days. The conservative
strategy discreetly improved oxygenation in patients
and increased the number of days without ventilation
(14.6 ± 0.5 vs. 12 ± 0.5, p < 0.001) but did not influence
mortality at 60 days, which was the principal purpose
of the study.
This study confirmed the impression that limiting the
fluid intake of patients with isolated respiratory failure
can limit respiratory morbidity without aggravating
other organ dysfunctions. However, the exclusion of
hemodynamically unstable patients or patients with
renal failure makes impossible to generalize these results
or to create a “gold standard” for management of the fluid
status of every ARDS patient. In addition, the absence of
an effect on mortality reminds us that the management of
fluid intake in ICU patients does not boil down to being
liberal or conservative. It is only once the initial phase of
hemodynamic instability has passed that a reasonable
policy of fluid intake aimed at zero fluid can contribute to
reducing the duration of ventilation and ICU stay [68].
The importance of a “biphase” fluid strategy was recently
illustrated by a retrospective study that included 212
patients presenting acute lung injury complicating septic
shock [69].
In this study, the nonperformance of early adapted
fluid administration and the absence of a negative fluid
balance during a minimum of the first 2 consecutive
days within the 7 days following the occurrence of septic
shock were independent mortality factors in multivariate
analysis. Along these lines, the Surviving Sepsis Campaign
[70] recommends a conservative fluid strategy for patients
with established ARDS who do not have evidence of tissue
hypoperfusion. From a hemodynamic point of view, in
case of a decrease in plasmatic oncotic pressure, which is
clinically illustrated by hypoprotidemia/hypoalbuminemia,
pulmonary edema forms at a lower hydrostatic pressure
because the oncotic pressure gradient between plasma andthe interstitium decreases [71]. Therefore, hypoprotidemia
frequently observed in ICU patients facilitates the devel-
opment of hydrostatic pulmonary edema. However, the
importance of oncotic pressure in the limitation of flux is
only conceivable if the barrier is intact. In case of endothe-
lial lesions, an interstitial edema will be all the richer in
proteins than the plasma, theoretically limiting the interest
of increasing the plasmatic oncotic pressure [72]. The
interest of a strategy of diuretic treatment associated with
albumin filling in ARDS patients with a protidemia infer-
ior to 50 g/l has been investigated by Martin et al. [73,74].
In the most recent study [74], 40 patients were random-
ized receiving either furosemide alone or furosemide and
albumin (75 g/d) for 3 days. When protidemia was super-
ior to 80 g/l in the treated group, albumin was replaced
with a placebo. Albuminemia increased by 13 g/l in the
albumin + furosemide group, reaching 30 g/l at the end of
treatment and increased by 3 g/l in the furosemide alone
group, reaching 20 g/l at the end of treatment. The effects
can be summarized by a discrete improvement in oxygen-
ation when albumin was associated with diuretic treatment
compared with diuretic treatment alone.
A large, randomized study [75] demonstrated that
volume therapy using albumin was equivalent to volume
therapy using saline in ICU patients. At this time, the very
limited clinical data do not make it possible to recommend
the administration of albumin with the goal to improve
pulmonary function and respiratory morbidity in ARDS
patients. Two recent RCTs evaluated the effects of albumin
in septic patients [76,77]. In the first, conducted in France
[76], 798 patients with septic shock were randomized to
receive either 300 ml of 20% albumin per day for 3 days or
the same amount of saline. Neither mortality at day 28 nor
the respiratory outcome was different between groups.
The second was conducted in Italy [77] and included
1,800 patients with severe sepsis or septic shock. Patients
were randomized to receive crystalloids and albumin to
maintain albumin level >30 g/l until day 28 or crystalloids
alone. Although day-90 mortality was not different
between groups, the use of albumin in the subgroup of
patients with septic shock was associated with a reduction
of mortality.
No large study investigated the interest of using
hydroxyethylstrach (HES) for fluid loading in ARDS
patients. However, considering the increased risk of renal
dysfunction associated with their use [78], especially in sep-
tic patients [79], they cannot be recommended in ARDS
patients. The use of hyperosmolar filling solutions, such as
hypertonic saline, could have the advantage, due to the lim-
ited amount of fluid administered, of limiting the develop-
ment of pulmonary edema in case of an increase in the
alveolocapillary barrier. Experimental studies have provided
conflicting results on this point [80-82]. In clinical practice,
the potential interest of hypertonic resuscitation has been
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In a recent randomized study that included 853 patients,
fluid loading with hypertonic saline or hypertonic saline/
dextran neither reduced mortality nor prevented ARDS
occurrence compared with normal saline resuscitation [83].
β2-agonists
Recovery from ARDS requires that the pulmonary
edema resolve [84]. The resolution of alveolar edema is
driven by active transport of sodium and chloride ions
from the luminal space across alveolar epithelial cells,
creating an osmotic gradient for the reabsorption of
water. Despite severe epithelial lesions, alveolar clearance is
usually pharmacologically stimulable. Several experimental
studies have shown that the exogenous administration of
cAMP agonists, in particular β2-agonists, accelerates the
resolution of edema, whatever its nature [85]. A preliminary
study [86] showed that the intravenous administration of
salbutamol at a dose of 15 μg/kg/h for 7 days in ARDS
patients made possible to diminish the quantity of pulmon-
ary water measured by transpulmonary thermodilution
without affecting oxygenation, duration of mechanical
ventilation, or outcome. However, the same authors
showed in a large RCT involving 326 patients [87] that
15 μg/kg/h of intravenous salbutamol was poorly tolerated
and was associated with an increase in 28-day mortality
(34 vs. 23% in the control group, p = 0.033). Another RCT
has evaluated the effect of aerosolized albuterol six times
per day until day 10 or extubation in patients with acute
lung injury [88]. The study was stopped for futility after
the inclusion of 282 patients. The number of ventilator-
free days, which was the primary outcome variable, was
not different between groups. These data do not support
the use of aerosolized β2-agonists to improve outcome in
patients with ARDS, and strongly suggest that intravenous
salbutamol may worsen outcome in those patients.
Corticosteroids
Corticosteroids have a broad inhibitory action on host
defenses, including inhibition of the transcription of
proinflammatory cytokines, inhibition of neutrophil acti-
vation, a synergic action with anti-inflammatory cytokines,
and a suppression of the synthesis of phospholipase A2,
cyclooxygenase, and inducible NO synthase [89]. Because
of these properties, corticosteroids in high doses for a
short period were proposed in the early phase of ARDS,
mostly in septic patients, to obtain a quick resolution and
to prevent progression to lung fibrosis.
Four randomized trials investigated early use of high
doses of corticosteroids for the prevention of ARDS in
septic shock patients [90-92] or in patients with confirmed
ARDS [93]. In these studies, corticosteroids significantly
reduced the duration of mechanical ventilation. However,
these studies showed no benefit in terms of prevention orimprovement of ARDS and no effect or even an increase
of mortality with corticosteroids. Only relevant ARDS eti-
ologies (pneumocystis pneumonia, pulmonary eosinophilic
pneumonia associated with certain autoimmune diseases,
or a systemic disease) are recognized as eligible for steroids
in the early stages. However, some authors argue that the
failure of steroids is not related to their early use but to a
too short administration [94]. Corticosteroids have an
inhibitory effect on fibroblast proliferation and colla-
gen deposition, including in the lung. Therefore, they
were proposed in the late phase of fibroproliferation
and post-aggressive fibrosis. Several case reports and a
small, randomized study suggested an interest in terms
of reduced mortality [95]. This study, although on a
small number of patients and despite methodological
bias has long been the benchmark to justify corticosteroids
in persistent ARDS.
More recently, another RCT by Meduri evaluated early
corticosteroid administration, and showed that methyl-
prednisolone administration (1 mg/kg/d) less than 72
after the onset of ARDS reduced mortality [96]. How-
ever, these results should be interpreted with caution,
because this study included a large number of patients
with septic shock. Another randomized, controlled trial,
conducted by the ARDS network, showed no reduction
in mortality in the group receiving methylprednisolone
[44]. This study involved 180 patients with ARDS per-
sistent after 7 to 28 days who received methylpredniso-
lone (2 mg/kg/d) or placebo for 21 days. The protocol
used was borrowed from corticosteroid Meduri study [95]
and also is the protocol commonly used in clinical practice.
Despite the lack of benefit in terms of mortality at 60 days,
an increased PaO2 to FiO2 ratio and thoracopulmonary
compliance were found in the group receiving corticoste-
roids, as well as shorter durations of mechanical ventilation
and ICU stay. The subgroup analysis showed a significantly
higher mortality rate when corticosteroid therapy was
started after the 13th day of ARDS, suggesting the presence
of fixed fibrotic lesions at this stage, at the expense of a
steroid-sensitive fibroproliferation. However, this study
had some bias, including a very important initial selec-
tion (5% of eligible patients included) with an only 30%
mortality rate in persistent ARDS, a brutal discontinu-
ation of steroids after 48 hours of ventilator weaning
and finally the absence of pathologic analysis leading
probably to a treatment with corticosteroids in some
patients without fibroproliferation. The subgroup ana-
lysis suggests this hypothesis. Indeed, patients with a
low level of procollagen III in their alveolar lavage
fluid, thus having a lesser degree of fibroproliferation,
had a higher mortality if they had received steroids
(35% vs. 9%, p < 0.05) [44]. On the other hand, it is conceiv-
able that some of them were carrying a contraindication to
steroids because of an infection.
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of persistent ARDS patients actually had fibrosis or
fibroproliferation highlighted on surgical biopsies and
that more than half of them had an infectious contraindi-
cation to systemic corticosteroids, notably because they
presented with an untreated infection. Conflicting data
exist on the interest of low doses of corticosteroids
(200 mg/day of hydrocortisone) in ARDS patients. A
post hoc analysis [98] of an RCT of low doses of ste-
roids in septic shock patients [99] noted that mortality
was improved mainly in the subgroup of patients with
ARDS and no response to corticotrophin stimulation.
On the other hand, two recent studies suggested that early
treatment with low doses of corticosteroids was inefficient
or even harmful in patients with H1N1 pneumonia [100]
or ARDS [101]. Further randomized, controlled trials are
needed before any definitive conclusion.
In the context of a persistent ARDS with histological
proof of fibroproliferation, a corticosteroid treatment can
be proposed according to the protocol by Meduri et al.,
with a progressive decrease of doses [95]. This protocol is
accompanied by measures usually applied in case of
prolonged corticosteroid therapy (gastric protection,
prevention of electrolyte disorders, treatment of diabetes,
restriction of the use of NMBs) to which can be added
a systematic bacteriological monitoring supplemented
by other sampling in case of suspicion of infection.
One of the main complications of corticosteroid treatment
is ICU acquired weakness [54,55], potentially reversible but
often leading to difficulties in weaning from ventilation.
Conclusions
The place of iNO as a rescue therapy has been clarified
by numerous studies that gave practical guidelines on its
use. The modest reduction of ventilation duration
obtained with a conservative fluid strategy for patients
who do not have evidence of tissue hypoperfusion makes
impossible to create a “gold standard” for management
of the fluid status of every ARDS patient. Further stud-
ies must confirm recent data from the literature, which
provide a strong argument for beneficial effects of
NMBs during the early phase of severe ARDS. Concerning
corticosteroids, numerous questions remain on their
potential benefits in subgroups of ARDS patients.
Finally, current and future research has to consider
the interest of therapeutics designed to reduce lung
inflammation and to enhance alveolar repair. Some of
the promising research areas include cell-based ther-
apy with mesenchymal stem cells, which could reverse
the major abnormalities of lung injury [102], statin
therapy [103], anti-inflammatory drugs, such as as-
pirin [104], or the modulation of signaling pathway of
proteins involved in the regulation of vascular perme-
ability [105,106].Competing interests
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